Effectiveness of a six-month isoniazid on prevention of incident tuberculosis among people living with HIV in Eritrea: a retrospective cohort study

Mulugeta Russom\textsuperscript{1,2,6}, Henok G. Woldu\textsuperscript{3}, Araia Berhane\textsuperscript{4}, Daniel YB. Jeannetot\textsuperscript{2}, Bruno H. Stricker\textsuperscript{5}, Katia Verhamme\textsuperscript{2}

\textsuperscript{1}Eritrean Pharmacovigilance Centre, National Medicines and Food Administration, Ministry of Health, Asmara, Eritrea.
\textsuperscript{2}Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, the Netherlands.
\textsuperscript{3}The Center for Health Analytics for National and Global Equity, Columbia, MO, USA.
\textsuperscript{4}Communicable Disease Control Division, Department of Public Health, Ministry of Health, Asmara, Eritrea.
\textsuperscript{5}Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands.
\textsuperscript{6}European Program for Pharmacovigilance and Pharmacoepidemiology, University of Bordeaux, Bordeaux, France.

Correspondence: Mulugeta Russom, e-mail: satiswt@gmail.com
S1: Classification of patients’ level of adherence to ART/IPT in Eritrea during the study period conducted between November 1, 2014 and November 1, 2020

| Adherence category to ART/IPT | definition | Remarks |
|-------------------------------|------------|---------|
| Good                          | >95%       | A patient was considered as having ‘good’ adherence if he/she missed ≤3 doses per month. |
| Fair                          | 85-94%     | A patient was considered as having ‘fair’ adherence if he/she missed 4-8 doses per month. |
| Poor                          | <85%       | A patient was considered as having ‘poor’ adherence if he/she missed ≥9 doses per month. |

*ART: Anti-Retroviral Therapy; IPT: Isoniazid Preventive Therapy*
S2: Study Questionnaire
Effectiveness of Isoniazid Preventive Therapy on the Prevention of Tuberculosis among People Living with HIV in Eritrea: a Retrospective Cohort Study - 2020

Part I: Area/patient Identification

| Zoba | Hospital | Exposure status [HAART + IPT = 1 and HAART only = 2] | Patient serial number (start with 0001) |
|------|----------|------------------------------------------------------|----------------------------------------|

Part II: Patient socio-demographic characteristics

| S/No | Questions and Filter | Coding Categories | Skip |
|------|----------------------|-------------------|------|
| 201. | Patient card number   |                   |      |
| 202. | Age of the patient in completed years (take first recorded within study period) | | |
| 203. | Sex of the patient | Male .................. 1 |  |
|      |                      | Female ................ 2 | |
| 204. | Body weight in completed Kgs (take first recorded within study period) | | |
| 205. | Level of education | No formal education ........... 1 |  |
|      |                      | Primary .................. 2 | |
|      |                      | Secondary ................ 3 | |
|      |                      | Higher education ............ 4 | |
| 206. | Residence | Asmara ..................... 1 |  |
|      |                      | Outside Asmara ................ 2 | |
|      |                      | Other ..................... 3 |  |
| 207. | Known history of smoking? | Yes ......................... 1 |  |
|      |                      | No ..................... 2 | |
|      |                      | Unknown ..................... 3 |  |
| 208. | Smoking status | Current smoker ................ 1 |  |
|      |                      | Former smoker ................ 2 | |
|      |                      | Unknown ..................... 3 |  |
| 209. | Known history of alcohol use? | Yes ......................... 1 |  |
|      |                      | No ..................... 2 | |
|      |                      | Unknown ..................... 3 |  |
| 210. | CD4 count (take first record during the study period) | |  |
| 211. | Viral load (take first record during the study period) | |  |
| 212. | Employment status | Employed .................... 1 |  |
|      |                      | Unemployed .................. 2 | |
|      |                      | Unknown ..................... 3 |  |
| 213. | Any co-morbidities? | Yes ......................... 1 |  |
|      |                      | No ..................... 2 | |
|      |                      | Unknown ..................... 3 |  |
| 214. | What are the co-morbidities? | Diabetes ..................... A | |
|      |                      | Hypertension .................. B | |
|      |                      | Cancer ..................... C | |
|      |                      | COPD .......................... D |  |

208. Smoking status

209. Known history of smoking?

210. CD4 count (take first record during the study period)

211. Viral load (take first record during the study period)

212. Employment status

213. Any co-morbidities?

214. What are the co-morbidities?
|   |   |   |
|---|---|---|
| 215. | Any history of malnutrition during the study period? | Yes ................................. 1  
No ...................................... 2  
Unknown ................................ 3 |
| 216. | Any history of prison during the study period? | Yes ................................. 1  
No ...................................... 2  
Unknown ................................ 3 |
| 217. | Any history of close contact with a person having TB during the study period? | Yes ................................. 1  
No ...................................... 2  
Unknown ................................ 3 |
| 218. | Current follow-up status? | Still on follow-up ................... 1  
Transferred .......................... 2  
Lost-to-follow up .................... 3  
Died ................................... 4 |
| 219. | Date of death | ___/ ____ (date/month/year) |
| 220. | Possible cause of death (Multiple answers are possible) | TB ...................................... 1  
Other OIs including pneumonia ..... 2  
Hepatic injury .......................... 3  
Cancer ................................... 4  
Other, specify ............................. 6  
Unknown .................................. 5 |
| Part III: Exposure status, adherence and treatment outcome |   |   |
| 301. | Date HAART started? | ___/ ___ (date/month/year) |
| 302. | Date of last follow-up (in years or months) | ___/ ___ (date/month/year) |
| 303. | Type of HAART patient has taken during the study period? (If patient has shifted to multiple regimens, take the regimen taken for the longest period of time) | Nevirapine based .................... 1  
Efavirenz based ........................ 2  
Second-line .............................. 3  
Other (specify) ......................... 4 |
| 304. | Level of adherence of patient towards HAART? | Good ................................. 1  
Fair ..................................... 2  
Poor ..................................... 3  
Unknown .................................. 4 |
| 305. | Has the patient received IPT? | Yes ................................. 1  
No ...................................... 2 |
| 306. | Any history of interruption of IPT? | Yes ................................. 1  
No ...................................... 2  
Unknown .................................. 3 |
| 307. | Date IPT started? | ___/ ___ (date/month/year) |
| 308. | Date last refill of IPT? | ___/ ___ (date/month/year) |
| 309. | Total number of INH tablets/doses supplied (excluding the last refill) |   |
| 310. | Was the patient diagnosed with TB? | Yes ................................. 1  
No ...................................... 2  
Unknown .................................. 3 |
| 311. | When was the patient diagnosed with TB? (Multiple answers are possible) | Before Nov. 1, 2014 .................. A  
After Nov. 1, 2014 .................... B |
| 312. | If patient was diagnosed after November 1, 2014, was it before initiation of IPT? | Yes ................................. 1  
No ...................................... 2 |
| (If patient did not receive IPT, choose 'non applicable') | Unknown ................................ 3  |
|--------------------------------------------------------|----------------------------------------|
|                                                       | Not applicable ................................ 4 |
| 313. Date patient diagnosed with TB (provide means of diagnosis in the last column of the respective dates) | ___/ / _____ (date/month/year) |
|                                                       | ___/ / _____ (date/month/year) |
|                                                       | ___/ / _____ (date/month/year) |

**Part IV: Data collector’s detail:** Name: _____________________ Tel: ______________ Sig. __________
S3: Listing form for excluded cases of a study that assessed the effectiveness of Isoniazid Preventive Therapy (IPT) in people living with HIV in Eritrea conducted between Nov 1, 2014 and Nov 1, 2020

Hospital: _________________

| Serial No. | Card number | Reason for exclusion (code A, B, C, D, E or F as per the below listed criteria) | Serial No. | Card number | Reason for exclusion (code A, B, C, D, E or F as per the below listed criteria) |
|------------|-------------|--------------------------------------------------------------------------------|------------|-------------|--------------------------------------------------------------------------------|
| 1.         |             |                                                                                | 26.        |             |                                                                                |
| 2.         |             |                                                                                | 27.        |             |                                                                                |
| 3.         |             |                                                                                | 28.        |             |                                                                                |
| 4.         |             |                                                                                | 29.        |             |                                                                                |
| 5.         |             |                                                                                | 30.        |             |                                                                                |
| 6.         |             |                                                                                | 31.        |             |                                                                                |
| 7.         |             |                                                                                | 32.        |             |                                                                                |
| 8.         |             |                                                                                | 33.        |             |                                                                                |
| 9.         |             |                                                                                | 34.        |             |                                                                                |
| 10.        |             |                                                                                | 35.        |             |                                                                                |
| 11.        |             |                                                                                | 36.        |             |                                                                                |
| 12.        |             |                                                                                | 37.        |             |                                                                                |
| 13.        |             |                                                                                | 38.        |             |                                                                                |
| 14.        |             |                                                                                | 39.        |             |                                                                                |
| 15.        |             |                                                                                | 40.        |             |                                                                                |
| 16.        |             |                                                                                | 41.        |             |                                                                                |
| 17.        |             |                                                                                | 42.        |             |                                                                                |
| 18.        |             |                                                                                | 43.        |             |                                                                                |
| 19.        |             |                                                                                | 44.        |             |                                                                                |
| 20.        |             |                                                                                | 45.        |             |                                                                                |
| 21.        |             |                                                                                | 46.        |             |                                                                                |
| 22.        |             |                                                                                | 47.        |             |                                                                                |
| 23.        |             |                                                                                | 48.        |             |                                                                                |
| 24.        |             |                                                                                | 49.        |             |                                                                                |
| 25.        |             |                                                                                | 50.        |             |                                                                                |

A. Exposure to IPT/ART for less than one year during the follow-up period
B. IPT interrupted and could not complete the six months regimen
C. Transferred in, IPT completed, but no data on IPT start date
D. Unexposed to ART during follow-up period
E. Patient diagnosed with TB (had active TB) while starting ART
F. Others (Specify)